This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Circulating SARS-CoV-2 RNA (RNAemia) has been highlighted as a promising prognostic biomarker in hospitalized COVID-19 patients, as it is associated with disease severity and mortality, with an estimated prevalence of 10%. Further, they hypothesized that the acute and profound alterations in the innate and adaptive immune system in COVID-19 patients, especially in RNAemic patients, will be accompanied by marked changes in the circulating proteome and interactome and that the proteome in COVID-19 patients will highlight mechanistically relevant signatures and trajectories, when compared to non-COVID-19 sepsis and healthy controls. Thus far, proteomics studies have focused on the determination of protein biomarkers of COVID-19 severity, but have not assessed the longitudinal relationship between proteomic changes, RNAemia and 28-day mortality. In this paper, the group of Prof. Mayr at King’s College London assessed RNAemia, antibody response against SARS-CoV-2 and proteomic profiles in serial blood samples from COVID-19 patients admitted to two ICUs.
Their preprint, "SARS-CoV-2 RNAemia and proteomic biomarker trajectory inform prognostication in COVID-19 patients admitted to intensive care," has been posted to Research Square. It has been assigned a DOI and is now a permanent and citable part of the scholarly record. The DOI is: 10.21203/rs.3.rs-101592/v1
Mon, 30 November